Currently trading under a dime. "AMBS" - Follow on Twitter: @AmarantusBio
Posted on the AMBS Ihub Board today by beltegeuse:
A year ago, on 03 Aug 2012, ACAD closed at $1.5. Now, it is trading around $22. The Company has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a first-in-class treatment for Parkinson's disease psychosis. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, Inc.
With at least a dozen upcoming Orphan Indications, LymPro, NuroPro, MANF patents in Europe and the US, I see AMBS entering multiple collaborations with the leading pharmaceutical companies in the world over the next 12 months. LymPro validation (to be announced next week) and CLIA collaboration will take AMBS to $0.5-1.00. I expect AMBS to be trading atleast at $10 (150X current pps) by Dec 2014.
In a recently completed pre-clinical model of Parkinson's disease funded by MJFF, MANF corrected the neurological deficits when it was given immediately after the animals became sick. MANF also corrected the neurological deficits when it was given three weeks after the models became sick. This means that MANF is able to prevent the death of healthy dopaminergic neurons, but also MANF can save dopaminergic neurons that are already dying.
How do these results apply to human patients? The results suggest that in patients newly diagnosed with Parkinson's disease MANF might be able to save those dopaminergic neurons that are sick and dying, but not yet dead. These patients will likely get better sooner, and their recovery will also last for a longer time. It is much too soon to predict whether MANF will be able to cure Parkinson's disease. MANF is certainly one of the most promising molecules currently in development to treat this debilitating disease.
Amarantus Appoints Dr. Colin Bier to Advisory Board for LymPro Commercialization
SUNNYVALE, Calif., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS) a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to neurodegeneration and apoptosis, today announced the appointment of Dr. Colin Bier to its Corporate Advisory Board to assist in the commercialization of the LymPro Test® as an aid in the diagnosis of the Alzheimer's type. Dr. Bier brings over 35 years of clinical expertise to the Company, having participated in numerous clinical trials, including trials in Alzheimer's disease as well as having been associated with the commercialization of several diagnostic tests.
"Dr. Bier brings significant expertise to the Company in the commercialization of diagnostic tests both through CLIA and through the FDA," said Gerald E. Commissiong, President & CEO of Amarantus. "Dr. Bier is one of the few people who has experience at the FDA concerning the intricacies of bringing a diagnostic test to market for Alzheimer's disease. We believe this regulatory experience will be highly valuable as we navigate the regulatory landscape and seek to bring LymPro to the broader physician-patient community."
Dr. Bieris managing and scientific director of ABA BioResearch, an independent bioregulatory consulting company providing expertise for technology assessment, fairness evaluation, due diligence and technical representation. Dr. Bier has extensive regulatory experience in the strategic management and development of pharmaceuticals, biopharmaceuticals, medical devices and diagnostics. Dr. Bier received his doctorate in experimental pathology from Colorado State University in 1978 and then pursued additional training as a Medical Research Council Postdoctoral Fellow and the Dr. Douglas James Fellow in the Department of Pathology, McGill University. Dr. Bier has extensive management exp
Posted by salexander1 on Ihub today:
I am truly amazed how many investors and shareholders just don't get what's going on here (connect the dots). A multi platform drug technology that could be used in:
b) Diabetes (just received a major. $.5mm grant days ago)
c) Ischemic Heart Disease
d) Retinitis Pigmentosa (Orphan indication already announced)
e) Traumatic Brain injury
g) Ear (supposedly, this Orphan indication will be announced shortly as well)
A Diagnostic division ...that already has an relationship (alliance_ with Becton Dickinson (for their Alzheimer's based blood test) that should be commercialized by 2014 (over $500mm in potential sales) and has many other Blood based tests for Parkinson's, Breast cancer (in the works) as well.
A strong patent portfolio, and a world class Advisory team with the following backgrounds (Bayer, Novartis, Merck, Bristol Myers Squibb backgrounds along with the Co founder of Amgen ..have been and are still consulting and advising the company on next steps regarding their business plan).
In addition, it entered into a letter of intent to in-license a Phase 2 drug candidate in L-Dopa-Induced Dyskinesia Parkinson’s Disease from an undisclosed third party. Once licensed the Company intends to initiate a Phase 2b clinical trial within 12 months.
Also, it has Dominion Capital who is funding their capital needs and is on board and committed to helping management execute the business plan.
In summary, why would anybody want to sell shares in a company with enormous potential (Market cap only at $34mm....still in its infancy)? GLTA!!!